Literature DB >> 11189821

Prevalence of hepatitis C among injection drug users in England and Wales: is harm reduction working?

V D Hope1, A Judd, M Hickman, T Lamagni, G Hunter, G V Stimson, S Jones, L Donovan, J V Parry, O N Gill.   

Abstract

OBJECTIVES: This study sought to establish the prevalence of hepatitis C antibodies (anti-HCV) and hepatitis B antibodies (anti-HBc) among injection drug users in England and Wales.
METHODS: A voluntary cross-sectional survey collected oral fluid samples and behavioral information; 2203 injectors were recruited through drug agencies, and 758 were recruited in the community.
RESULTS: Prevalence was 30% for anti-HCV, 21% for anti-HBc, and 0.9% for HIV antibodies. Anti-HCV prevalence rates were significantly greater among those with longer injecting careers, those in older age groups, those residing in London, those recruited in drug agencies, those positive for anti-HBc, and those with a previous voluntary HIV test.
CONCLUSIONS: Anti-HCV prevalence rates among injectors in England and Wales, where comprehensive harm reduction programs exist, are lower than rates in other industrialized countries.

Entities:  

Mesh:

Year:  2001        PMID: 11189821      PMCID: PMC1446497          DOI: 10.2105/ajph.91.1.38

Source DB:  PubMed          Journal:  Am J Public Health        ISSN: 0090-0036            Impact factor:   9.308


  29 in total

1.  Prevalence of HIV, hepatitis B, and hepatitis C antibodies in prisoners in England and Wales: a national survey.

Authors:  A R Weild; O N Gill; D Bennett; S J Livingstone; J V Parry; L Curran
Journal:  Commun Dis Public Health       Date:  2000-06

2.  A short questionnaire (IRQ) to assess injecting risk behaviour.

Authors:  G V Stimson; S Jones; C Chalmers; D Sullivan
Journal:  Addiction       Date:  1998-03       Impact factor: 6.526

3.  Hepatitis B and hepatitis C virus infections: risk factors among drug users in Northwest England.

Authors:  K H Lamden; N Kennedy; N J Beeching; D Lowe; C L Morrison; H Mallinson; K J Mutton; Q Syed
Journal:  J Infect       Date:  1998-11       Impact factor: 6.072

4.  HIV-1 prevalence in community-wide samples of injecting drug users in London, 1990-1993.

Authors:  G V Stimson; G M Hunter; M C Donoghoe; T Rhodes; J V Parry; C P Chalmers
Journal:  AIDS       Date:  1996-06       Impact factor: 4.177

5.  Reduced risk of hepatitis B and hepatitis C among injection drug users in the Tacoma syringe exchange program.

Authors:  H Hagan; D C Jarlais; S R Friedman; D Purchase; M J Alter
Journal:  Am J Public Health       Date:  1995-11       Impact factor: 9.308

6.  Incidence of bloodborne virus infection and risk behaviours in a cohort of injecting drug users in Victoria, 1990-1995.

Authors:  N Crofts; C K Aitken
Journal:  Med J Aust       Date:  1997-07-07       Impact factor: 7.738

7.  Prevalence of antibodies to hepatitis B, hepatitis C, and HIV and risk factors in Irish prisoners: results of a national cross sectional survey.

Authors:  S Allwright; F Bradley; J Long; J Barry; L Thornton; J V Parry
Journal:  BMJ       Date:  2000-07-08

8.  Detection of antibodies against hepatitis C virus in saliva: a marker of viral replication.

Authors:  S O Cameron; K S Wilson; T Good; J McMenamin; B McCarron; A Pithie; R Fox
Journal:  J Viral Hepat       Date:  1999-03       Impact factor: 3.728

9.  Molecular epidemiology of hepatitis C virus infection amongst intravenous drug users in rural communities.

Authors:  A Majid; R Holmes; U Desselberger; P Simmonds; T A McKee
Journal:  J Med Virol       Date:  1995-05       Impact factor: 2.327

10.  Hepatitis C virus antibody prevalence among injecting drug users in Glasgow has fallen but remains high.

Authors:  D Goldberg; S Cameron; J McMenamin
Journal:  Commun Dis Public Health       Date:  1998-06
View more
  19 in total

1.  Illegal drug use in the age of ageing.

Authors:  Caryl Beynon; Gerry Stimson; Euan Lawson
Journal:  Br J Gen Pract       Date:  2010-07       Impact factor: 5.386

2.  Survival of hepatitis C virus in syringes: implication for transmission among injection drug users.

Authors:  Elijah Paintsil; Huijie He; Christopher Peters; Brett D Lindenbach; Robert Heimer
Journal:  J Infect Dis       Date:  2010-10-01       Impact factor: 5.226

3.  A time since onset of injection model for hepatitis C spread amongst injecting drug users.

Authors:  S Corson; D Greenhalgh; S J Hutchinson
Journal:  J Math Biol       Date:  2012-08-28       Impact factor: 2.259

4.  Prevalence of hepatitis and HIV infections and vaccination rates in patients entering the heroin-assisted treatment in Switzerland between 1994 and 2002.

Authors:  Miriam Gerlich; Patrick Gschwend; Ambros Uchtenhagen; Alexander Krämer; Jürgen Rehm
Journal:  Eur J Epidemiol       Date:  2006-07-21       Impact factor: 8.082

5.  Hepatitis C virus: laboratory surveillance in England and Wales, 1992-2004.

Authors:  U Gungabissoon; M A Balogun; M E Ramsay
Journal:  Epidemiol Infect       Date:  2006-09-06       Impact factor: 2.451

6.  Clinical course of hepatitis C virus during the first decade of infection: cohort study.

Authors:  Helen E Harris; Mary E Ramsay; Nick Andrews; Keith P Eldridge
Journal:  BMJ       Date:  2002-02-23

7.  Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users.

Authors:  Charlotte H S B van den Berg; Colette Smit; Margreet Bakker; Ronald B Geskus; Ben Berkhout; Suzanne Jurriaans; Roel A Coutinho; Katja C Wolthers; Maria Prins
Journal:  Eur J Epidemiol       Date:  2007-03-03       Impact factor: 8.082

8.  Hepatitis C virus infection among drug injectors in St Petersburg, Russia: social and molecular epidemiology of an endemic infection.

Authors:  Elijah Paintsil; Sergei V Verevochkin; Elena Dukhovlinova; Linda Niccolai; Russell Barbour; Edward White; Olga V Toussova; Louis Alexander; Andrei P Kozlov; Robert Heimer
Journal:  Addiction       Date:  2009-08-27       Impact factor: 6.526

9.  Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place.

Authors:  Holly Hagan; Enrique R Pouget; Don C Des Jarlais; Corina Lelutiu-Weinberger
Journal:  Am J Epidemiol       Date:  2008-10-09       Impact factor: 4.897

10.  The phylogenetic analysis of hepatitis C virus isolates obtained from two Iranian carriers revealed evidence for a new subtype of HCV genotype 3.

Authors:  Safieh Amini; Malek-Hossein Ahmadi Pour; Kayhan Azadmanesh
Journal:  Virus Genes       Date:  2006-12       Impact factor: 2.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.